HanAll Biopharma Co., Ltd.
HanAll Biopharma is a KOSPI-listed (009420) company based in Seoul. Its dry-eye candidate tanfanercept (HL036) is in Phase 3 in the United States.
| Headquarters | Seoul, South Korea |
|---|---|
| Listing | KOSPI:009420 |
| Lead asset / stage | tanfanercept (HL036) Phase 3 — United States |
| Latest event | HanAll reported its third-quarter 2026 financial results. |